No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IDXX240517C590000
- 0.07
- +0.02+40.00%
15min DelayTrading May 14 09:34 ET
0.08High0.07Low
0.08Open0.05Pre Close12 Volume8 Open Interest590.00Strike Price94.00Turnover53.60%IV13.47%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.07Time Value100Contract SizeAmericanOptions Type0.0080Delta0.0008Gamma7428.93Leverage Ratio-0.0572Theta0.0004Rho59.47Eff Leverage0.0110Vega
Intraday
- 5D
- 1D
News
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President,
IDEXX Labs Is Maintained at Overweight by Morgan Stanley
IDEXX Labs Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620
IDEXX Laboratories (IDXX) has an average outperform rating and a price target range of $400 to $641, according to analysts polled by Capital IQ. Price: 500.30, Change: -2.72, Percent Change: -0.54
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Potentially Undervalued?
Let's talk about the popular IDEXX Laboratories, Inc. (NASDAQ:IDXX). The company's shares saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$577 and f
U.S. Pledges Nearly $200M to Prevent Bird Flu Spread on Dairy Farms
IDEXX Laboratories (NASDAQ:IDXX) Knows How To Allocate Capital
Comments
$IDEXX Laboratories Inc(IDXX.US$ 👀 Here's How Much You Would Have Made Owning
IDEXX Laboratories Stock In The Last 15 Years!
IDEXX Laboratories Stock In The Last 15 Years!
The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
Long-term performance of IDEXX shows positive returns despite recent downturn. Market caution and strong momentum warrant closer scrutiny. Nonetheless, investors should note the existent 2 warning signs.
Comment:
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Read more